Wall Street is positive on Millendo Therapeutics Inc (MLND). On average, analysts give the stock a Buy rating. The average price target is $3.333, which means analysts expect the stock to add by 70.05% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 20, which is better than 20% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers.
InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.
What's Happening With Millendo Therapeutics Inc Stock Today?
Millendo Therapeutics Inc (MLND) stock is up 5.38% while the S&P 500 is lower by -1.05% as of 11:03 AM on Friday, Jan 29. MLND is higher by $0.10 from the previous closing price of $1.86 on volume of 451,241 shares. Over the past year the S&P 500 has gained 14.13% while MLND is lower by -76.83%. MLND lost -$2.41 per share the over the last 12 months.